guinea
pig
virusan
anim
model
ebov
infect
pathogenesi
develop
inbr
strain
guinea
pig
us
armi
medic
research
institut
infecti
diseas
serial
passag
zair
speci
ebov
zebov
mayinga
isol
time
result
guinea
strain
give
rise
high
plasma
viremia
typic
pfuml
highli
lethal
guinea
pig
typic
caus
death
day
challeng
infect
experi
perform
biosafeti
level
bsl
biocontain
research
conduct
complianc
anim
welfar
act
feder
statu
regul
relat
anim
experi
involv
anim
adher
principl
state
guid
care
use
laboratori
anim
facil
use
fulli
accredit
associ
assess
accredit
laboratori
anim
care
intern
noninfecti
mous
guinea
pig
clearanc
biodistribut
experi
conduct
protiva
biotherapeut
accord
guidelin
canadian
council
anim
care
sirnassirna
design
target
individu
region
zebov
l
gene
accord
tuschl
rule
avail
http
wwwrockefelleredulabheadstuschlsirnahtml
sirna
duplex
chemic
synthes
dharmacon
trilink
biotechnolog
sequenc
use
design
follow
sens
antisens
sens
antisens
sens
antisens
sens
antisens
sens
antisens
lipid
encapsul
sirnasirna
encapsul
process
spontan
vesicl
format
report
jeff
et
al
snalp
compos
synthet
cholesterol
sigma
phospholipid
dspc
avanti
polar
lipid
peg
lipid
pegcdma
poli
ethylen
glycol
carbamoyl
cation
lipid
dlindma
ndimethylaminopropan
molar
ratio
pegcdma
dlindma
synthes
describ
elsewher
result
snalp
dialyz
pb
filter
steril
filter
use
particl
size
rang
nm
typic
sirna
found
encapsul
within
liposom
cellcultur
experimentssirna
pmol
transfect
vero
cell
use
oligofectamin
invitrogen
accord
manufactur
instruct
h
transfect
vero
cell
infect
zebov
moi
cultur
fluid
collect
h
determin
level
infecti
zebov
vero
cell
collect
immunofluoresc
stain
vivo
pharmacokinet
tissu
distributionradiolabel
snalp
prepar
plasma
clearanc
biodistribut
experi
incorpor
nonexchang
lipid
label
cholesteryl
oleyl
ether
che
per
milligram
total
lipid
snalp
administ
singl
bolu
mg
sirna
per
kilogram
bodi
weight
femal
male
hartley
guinea
pig
charl
river
laboratori
via
ear
vein
inject
blood
collect
via
contralater
ear
nick
cours
h
h
guinea
pig
kill
inhal
harvest
tissu
homogen
lyse
matrix
tube
mp
biomed
contain
distil
water
homogen
assay
radioact
liquid
scintil
count
picofluor
tissu
picofluor
blood
perkinelm
sirna
treatment
zebov
challeng
guinea
pig
sirna
nmol
total
mix
polyethylenimin
pei
vivo
jetpei
qbiogen
np
ratio
room
temperatur
min
accord
manufactur
instruct
guinea
pig
treat
via
intraperiton
ip
inject
pei
polyplex
correspond
mgkg
sirna
three
hour
treatment
guinea
pig
challeng
via
subcutan
sc
inject
pfu
guinea
zebov
guinea
pig
receiv
addit
treatment
pei
polyplex
prepar
describ
immedi
administr
h
zebov
challeng
experi
evalu
snalp
deliveri
system
snalpformul
sirna
administ
ip
h
challeng
guinea
pig
via
sc
inject
pfu
guinea
zebov
guinea
pig
receiv
addit
treatment
snalpformul
sirna
h
zebov
challeng
guinea
pig
care
monitor
sign
diseas
surviv
cours
experi
viru
titrat
plaqu
assayviru
titrat
perform
convent
plaqu
assay
vero
cell
cellcultur
fluid
blood
collect
guinea
pig
describ
elsewher
immunofluoresc
assaycel
fix
neutralbuff
formalin
h
inactiv
infecti
zebov
fixat
cell
wash
copiou
amount
pb
process
immunofluoresc
stain
viral
protein
briefli
cell
incub
readytous
proteinas
k
dako
min
room
temperatur
cell
wash
pb
block
normal
goat
serum
kpl
laboratori
min
room
temperatur
viral
antigen
detect
incub
cell
mous
monoclon
antibodi
guinea
zebov
min
room
temperatur
rins
pb
incub
conjug
invitrogen
min
room
temperatur
cell
counterstain
evan
blue
aid
visual
percentag
antigenposit
cell
determin
examin
random
field
fluoresc
vivo
cytokin
inductionsnalp
administ
ml
pb
icr
mice
harlan
standard
iv
inject
later
tail
vein
blood
collect
cardiac
punctur
h
administr
process
plasma
cytokin
analysi
level
mous
cytokin
interferon
ifn
measur
use
sandwich
elisa
kit
pbl
biomed
accord
manufactur
instruct
determin
whether
sirna
inhibit
replic
zebov
vitro
first
transfect
vero
cell
either
pool
differ
sirna
specif
zebov
l
gene
equival
dose
irrelev
scrambl
sequenc
use
vero
cell
lack
structur
gene
thu
preclud
confound
effect
cytokin
variou
time
point
transfect
h
transfect
cell
infect
zebov
cell
cultur
fluid
harvest
h
later
determin
level
viru
product
result
show
sirna
pool
inhibit
product
infecti
zebov
depend
transfect
cell
infect
figur
immunofluoresc
antibodi
stain
abl
demonstr
mean
sd
reduct
student
test
number
cell
express
ebov
protein
figur
individu
test
l
sirna
yield
similar
result
data
shown
irrelev
scrambl
sequenc
inhibit
product
infecti
zebov
fail
reduc
number
cell
express
ebov
protein
figur
test
whether
pool
sirna
could
protect
guinea
pig
lethal
zebov
challeng
although
mous
guinea
pig
model
avail
zebov
infect
chose
use
guinea
pig
experi
appear
basi
evalu
coagul
chang
reproduc
human
filovir
infect
slightli
better
mice
mous
model
avail
filovirus
wherea
guinea
pig
use
studi
sudan
speci
ebov
model
infect
sever
strain
ebovrel
marburg
viru
first
vivo
experi
guinea
pig
treat
either
l
sirna
pool
irrelev
scrambl
sequenc
mix
pei
inject
retroorbit
h
zebov
challeng
guinea
pig
receiv
equival
dose
sirna
mgkg
h
zebov
challeng
signific
reduct
plasma
viremia
demonstr
day
challeng
guinea
pig
receiv
l
sirna
pool
compar
guinea
pig
receiv
irrelev
scrambl
sequenc
figur
control
guinea
pig
treat
irrelev
scrambl
sequenc
die
euthan
day
challeng
wherea
guinea
pig
treat
sirna
pool
surviv
guinea
pig
either
die
euthan
day
respect
improv
potenc
l
sirna
encapsul
lipid
particl
previous
shown
antivir
efficaci
mous
model
hbv
infect
snalp
method
yield
particl
uniform
reproduc
perform
specif
regardless
sirna
payload
particl
size
snalp
prepar
use
present
studi
nm
polydispers
encapsul
effici
nucleic
acid
lipid
ratio
lipid
assess
plasma
clearanc
biodistribut
snalp
prepar
contain
nonexchang
lipid
label
describ
elsewher
plasma
clearanc
snalp
guinea
pig
determin
singl
iv
administr
previous
shown
iv
administr
unstabil
unformul
sirna
mice
result
rapid
elimin
plasma
compart
elimin
halflif
min
calcul
serum
halflif
snalp
use
present
studi
min
administr
guinea
pig
figur
liver
known
one
earli
primari
site
zebov
replic
rodent
nonhuman
primat
also
interest
determin
pattern
biodistribut
snalp
administr
shown
figur
substanti
quantiti
snalp
accumul
liver
within
h
inject
substanti
fewer
snalp
accumul
spleen
lung
brain
gonad
tissu
ovari
test
respect
thymu
mean
sd
remain
rel
inaccess
accumul
snalp
rapid
select
accumul
snalp
liver
compar
favor
result
target
deliveri
technolog
use
receptorligand
interact
well
result
target
technolog
evalu
pool
l
sirna
use
snalp
deliveri
system
rodent
model
ebov
hf
previou
challeng
experi
guinea
pig
receiv
sirna
pool
mgkg
control
guinea
pig
receiv
irrelev
scrambl
sequenc
mgkg
howev
experi
guinea
pig
treat
sirna
zebov
challeng
rather
treatment
initi
h
challeng
addit
treatment
administ
daili
day
infect
plasma
viremia
level
peak
day
guinea
pig
model
detect
day
guinea
pig
treat
sirna
pool
rang
pfuml
control
guinea
pig
figur
one
guinea
pig
treat
sirna
pool
die
day
like
toxic
given
unabl
demonstr
presenc
infecti
zebov
anim
anoth
guinea
pig
treatment
group
euthan
day
death
could
attribut
viral
replic
either
remain
guinea
pig
treat
sirna
pool
show
evid
ill
surviv
zebov
challeng
wherea
control
guinea
pig
die
euthan
day
figur
experi
perform
assess
efficaci
sirna
pool
lower
dose
individu
evalu
l
sirna
zebovinfect
guinea
pig
receiv
lower
dose
mgkg
sirna
pool
complet
protect
viremia
death
figur
although
vari
level
viremia
mortal
observ
among
group
treat
individu
sirna
figur
lowest
level
mortal
associ
guinea
pig
recent
studi
demonstr
synthet
sirna
induc
high
level
type
ifn
inflammatori
cytokin
mammalian
cell
immun
respons
could
contribut
antivir
efficaci
toxic
associ
system
administr
formul
sirna
immunostimulatori
properti
sirnacontain
snalp
examin
directli
iv
administr
mice
strikingli
snalpformul
sirna
includ
irrelev
scrambl
sequenc
induc
serum
inject
mice
figur
guinea
pig
mice
treat
immunostimulatori
snalp
show
symptom
system
toxic
includ
transient
decreas
bodi
weight
piloerect
data
shown
previous
shown
associ
sirnamedi
stimul
mammalian
innat
immun
system
advers
effect
evid
control
anim
treat
pb
anim
inject
empti
liposom
nake
sirna
note
confer
greatest
benefit
use
treat
zebovinfect
anim
least
immunostimulatori
sirna
examin
provid
evid
support
rnaispecif
antivir
effect
infect
experi
current
known
effect
pre
postexposur
therapi
human
ebov
infect
time
treat
patient
infect
ebov
consist
palli
care
direct
toward
maintain
blood
volum
electrolyt
balanc
number
heparin
convalesc
serum
equin
antiebov
use
treat
infect
human
andor
nonhuman
primat
result
inconsist
gener
littl
effect
although
number
postexposur
treatment
shown
promis
rodent
model
ebov
hf
none
shown
success
nonhuman
primat
date
postexposur
treatment
shown
protect
nonhuman
primat
challeng
zebov
strategi
design
modul
manifest
diseas
rather
block
replic
viru
studi
rhesu
monkey
demonstr
postexposur
strategi
mitig
coagul
disord
typifi
ebov
infect
improv
surviv
howev
improv
efficaci
clearli
need
although
assur
snalpbas
sirna
strategi
describ
protect
ebov
infect
morerigor
nonhuman
primat
model
reason
optim
light
compar
data
histor
studi
specif
note
sever
previou
studi
shown
complet
postexposur
protect
mice
guinea
pig
lethal
zebov
challeng
howev
case
rodent
protect
viremia
subsequ
transit
strategi
nonhuman
primat
uniformli
unsuccess
protect
macaqu
lethal
infect
suggest
inabl
complet
inhibit
viremia
rodent
predict
unfavor
outcom
nonhuman
primat
present
studi
administr
sirna
unabl
detect
viremia
zebovchalleng
guinea
pig
clearli
observ
guarante
success
snalpbas
sirna
approach
nonhuman
primat
hand
offer
hope
prospect
success
least
improv
focus
l
gene
zebov
demonstr
vivo
util
snalp
technolog
futur
studi
focu
evalu
sequenc
ebov
gene
possibl
employ
cocktail
sirna
increas
antivir
effect
furthermor
uniqu
mechan
rnai
may
benefit
combin
sirna
treatment
ebov
infect
complementari
antivir
approach
immunoglobulin
coagul
inhibitor
